{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T06:36:06Z","timestamp":1783492566397,"version":"3.55.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["jsatjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Use and Addiction Treatment"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.josat.2023.209183","type":"journal-article","created":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T01:50:47Z","timestamp":1698025847000},"page":"209183","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Evaluation of an injectable monthly extended-release buprenorphine program in a low-barrier specialty addiction medicine clinic"],"prefix":"10.1016","volume":"156","author":[{"given":"Jessica","family":"Heil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Salzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krystal","family":"Hunter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlan E.","family":"Baston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Milburn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Haroz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie S.","family":"Ganetsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.josat.2023.209183_bb0005","series-title":"Provisional drug overdose death counts","first-page":"12","author":"Ahmad","year":"2021"},{"key":"10.1016\/j.josat.2023.209183_bb0010","series-title":"2019 ASAM annual conference poster abstracts","author":"Andorn","year":"2019"},{"key":"10.1016\/j.josat.2023.209183_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108959","article-title":"Tracing the affordances of long-acting injectable depot buprenorphine: A qualitative study of patients\u2019 experiences in Australia","volume":"227","author":"Barnett","year":"2021","journal-title":"Drug and Alcohol Dependence"},{"issue":"5","key":"10.1016\/j.josat.2023.209183_bb0020","doi-asserted-by":"crossref","first-page":"e219708","DOI":"10.1001\/jamanetworkopen.2021.9708","article-title":"Extended-release buprenorphine and its evaluation with patient-reported outcomes","volume":"4","author":"Compton","year":"2021","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.josat.2023.209183_bb0025","first-page":"1","article-title":"Extended-release buprenorphine outcomes among treatment resistant veterans","author":"Cotton","year":"2021","journal-title":"The American Journal of Drug and Alcohol Abuse"},{"key":"10.1016\/j.josat.2023.209183_bb0030","author":"FDA"},{"issue":"1","key":"10.1016\/j.josat.2023.209183_bb0035","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/biomet\/80.1.27","article-title":"Bias reduction of maximum likelihood estimates","volume":"80","author":"Firth","year":"1993","journal-title":"Biometrika"},{"issue":"10173","key":"10.1016\/j.josat.2023.209183_bb0040","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/S0140-6736(18)32259-1","article-title":"Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"393","author":"Haight","year":"2019","journal-title":"The Lancet"},{"issue":"24","key":"10.1016\/j.josat.2023.209183_bb0045","doi-asserted-by":"crossref","first-page":"4216","DOI":"10.1002\/sim.2687","article-title":"A comparative investigation of methods for logistic regression with separated or nearly separated data","volume":"25","author":"Heinze","year":"2006","journal-title":"Statistics in Medicine"},{"key":"10.1016\/j.josat.2023.209183_bb0050","series-title":"Sublocade. In. Albany, NY","author":"Indivior","year":"2022"},{"issue":"4","key":"10.1016\/j.josat.2023.209183_bb0055","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s40262-020-00957-0","article-title":"Population pharmacokinetics of a monthly buprenorphine depot injection for the treatment of opioid use disorder: A combined analysis of phase II and phase III trials","volume":"60","author":"Jones","year":"2021","journal-title":"Clinical Pharmacokinetics"},{"issue":"1","key":"10.1016\/j.josat.2023.209183_bb0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13643-021-01764-9","article-title":"Retention in opioid agonist treatment: A rapid review and meta-analysis comparing observational studies and randomized controlled trials","volume":"10","author":"Klimas","year":"2021","journal-title":"Systematic Reviews"},{"issue":"22","key":"10.1016\/j.josat.2023.209183_bb0065","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/adaw.33796","article-title":"FDA approves Brixadi, new buprenorphine treatment option","volume":"35","author":"Knopf","year":"2023","journal-title":"Alcoholism & Drug Abuse Weekly"},{"key":"10.1016\/j.josat.2023.209183_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2021.108329","article-title":"Who stays in medication treatment for opioid use disorder? A national study of outpatient specialty treatment settings","volume":"126","author":"Krawczyk","year":"2021","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"1","key":"10.1016\/j.josat.2023.209183_bb0075","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/add.15116","article-title":"Polysubstance use and association with opioid use disorder treatment in the US veterans health administration","volume":"116","author":"Lin","year":"2021","journal-title":"Addiction"},{"issue":"5","key":"10.1016\/j.josat.2023.209183_bb0080","doi-asserted-by":"crossref","DOI":"10.1097\/ADM.0000000000000647","article-title":"Recovery from opioid use disorder (OUD) after monthly long-acting buprenorphine treatment: 12-month longitudinal outcomes from RECOVER, an observational study","volume":"14","author":"Ling","year":"2020","journal-title":"Journal of Addiction Medicine"},{"key":"10.1016\/j.josat.2023.209183_bb0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jsat.2019.11.004","article-title":"Effects of monthly buprenorphine extended-release injections on patient-centered outcomes: A long-term study","volume":"110","author":"Ling","year":"2020","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"6","key":"10.1016\/j.josat.2023.209183_bb0090","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1001\/jamainternmed.2018.1052","article-title":"Weekly and monthly subcutaneous buprenorphine depot formulations vs daily sublingual buprenorphine with naloxone for treatment of opioid use disorder: A randomized clinical trial","volume":"178","author":"Lofwall","year":"2018","journal-title":"JAMA Internal Medicine"},{"issue":"4","key":"10.1016\/j.josat.2023.209183_bb0095","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/ajad.13018","article-title":"Case series: Rapid induction onto long acting buprenorphine injection for high potency synthetic opioid users","volume":"29","author":"Mariani","year":"2020","journal-title":"The American Journal on Addictions"},{"issue":"5","key":"10.1016\/j.josat.2023.209183_bb0100","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/ajad.13193","article-title":"Open-label trial of a single-day induction onto buprenorphine extended-release injection for users of heroin and fentanyl","volume":"30","author":"Mariani","year":"2021","journal-title":"The American Journal on Addictions"},{"key":"10.1016\/j.josat.2023.209183_bb0105","article-title":"Long-acting injectable buprenorphine for opioid use disorder: A systematic review of impact of use on social determinants of health","volume":"108776","author":"Martin","year":"2022","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.josat.2023.209183_bb0110","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","volume":"2","author":"Mattick","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.josat.2023.209183_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108764","article-title":"Characterizing initiation, use, and discontinuation of extended-release buprenorphine in a nationally representative United States commercially insured cohort","volume":"225","author":"Morgan","year":"2021","journal-title":"Drug and Alcohol Dependence"},{"issue":"6","key":"10.1016\/j.josat.2023.209183_bb0120","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1093\/beheco\/arh107","article-title":"A farewell to Bonferroni: The problems of low statistical power and publication bias","volume":"15","author":"Nakagawa","year":"2004","journal-title":"Behavioral Ecology"},{"key":"10.1016\/j.josat.2023.209183_bb0125","series-title":"Medications for opioid use disorder save lives","author":"National Academies of Sciences, E., & Medicine","year":"2019"},{"key":"10.1016\/j.josat.2023.209183_bb0130","series-title":"Behavioral health 2016\u20132017: Technical report","author":"National Quality Forum","year":"2017"},{"key":"10.1016\/j.josat.2023.209183_bb0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugalcdep.2018.03.057","article-title":"Implants and depot injections for treating opioid dependence: Qualitative study of people who use or have used heroin","volume":"189","author":"Neale","year":"2018","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.josat.2023.209183_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2021.108316","article-title":"Real-world outcomes with extended-release buprenorphine (XR-BUP) in a low threshold bridge clinic: A retrospective case series","volume":"126","author":"Peckham","year":"2021","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.josat.2023.209183_bb0145","author":"RBP-6000"},{"key":"10.1016\/j.josat.2023.209183_bb0150","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/00001648-199001000-00010","article-title":"No adjustments are needed for multiple comparisons","author":"Rothman","year":"1990","journal-title":"Epidemiology"},{"issue":"7","key":"10.1016\/j.josat.2023.209183_bb0155","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1097\/MLR.0000000000000727","article-title":"Patterns of buprenorphine-naloxone treatment for opioid use disorder in a multi-state population","volume":"55","author":"Saloner","year":"2017","journal-title":"Medical Care"},{"key":"10.1016\/j.josat.2023.209183_bb0160","author":"SAMHSA"},{"key":"10.1016\/j.josat.2023.209183_bb0165","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jsat.2020.01.009","article-title":"Perceptions and preferences for long-acting injectable and implantable medications in comparison to short-acting medications for opioid use disorders","volume":"111","author":"Saunders","year":"2020","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.josat.2023.209183_bb0170","article-title":"Mortality risk during and after opioid substitution treatment: Systematic review and meta-analysis of cohort studies","volume":"357","author":"Sordo","year":"2017","journal-title":"bmj"},{"key":"10.1016\/j.josat.2023.209183_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2021.108661","article-title":"Retention in care for persons with opioid use disorder transitioning from sublingual to injectable buprenorphine","volume":"136","author":"Stein","year":"2022","journal-title":"Journal of Substance Abuse Treatment"}],"container-title":["Journal of Substance Use and Addiction Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949875923002345?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949875923002345?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T15:50:49Z","timestamp":1757433049000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949875923002345"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":35,"alternative-id":["S2949875923002345"],"URL":"https:\/\/doi.org\/10.1016\/j.josat.2023.209183","relation":{},"ISSN":["2949-8759"],"issn-type":[{"value":"2949-8759","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of an injectable monthly extended-release buprenorphine program in a low-barrier specialty addiction medicine clinic","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Use and Addiction Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.josat.2023.209183","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"209183"}}